Overview
Tirzep 2.5 mg is the standard initiation-strength formulation of Tirzepatide, a first-in-class dual glucose-dependent insulinotropic polypeptide (GIP) receptor and glucagon-like peptide-1 (GLP-1) receptor agonist. Manufactured by ACI Pharmaceuticals PLC and distributed internationally by Saif Pharma, Tirzep represents a paradigm shift in chronic metabolic care. It consists of a 39-amino-acid modified peptide engineered with a C20 fatty diacid moiety that facilitates albumin binding, prolonging its half-life to support a highly effective, once-weekly dosing profile.
Please note: While sometimes referred to broadly as “tablets” in digital catalogs, Tirzep is structurally a therapeutic peptide supplied exclusively as a sterile solution for subcutaneous injection to preserve molecular integrity and ensure therapeutic efficacy.
Therapeutic Applications
Tirzep 2.5 mg is indicated for:
Treatment Initiation for Glycemic Control: As a starting tier to improve glycemic control in adults with Type 2 Diabetes Mellitus alongside diet and exercise modification.
Metabolic Dose Initiation for Weight Management: As the primary induction phase for long-term chronic weight management in adults presenting with obesity or overweight comorbidities.
Important Clinical Guidance:
The 2.5 mg dosage is strictly for treatment initiation and is not intended for long-term effective glycemic control. Patients must be titrated up to maintenance doses (5 mg, 10 mg, 12.5 mg, or 15 mg) according to standard medical guidelines.
It has not been clinically studied in patients with a history of acute or chronic pancreatitis.
It is not indicated for the treatment of patients with Type 1 Diabetes Mellitus.
Mechanism of Action
Tirzep combines the power of two critical metabolic incretins into a single active molecule:
Dual Incretin Receptor Targeting: It selectively binds to and activates both native GIP and GLP-1 metabolic receptors.
Glucose-Dependent Insulin Management: It enhances both first- and second-phase insulin secretion from pancreatic beta cells while lowering circulating glucagon secretion. Because this action occurs strictly in a glucose-dependent manner, it works robustly when blood sugar is high and minimizes the baseline risk of severe hypoglycemia.
Satiety and Gastric Regulation: Tirzep stabilizes postprandial glucose levels by delaying gastric emptying and acting directly on CNS satiety centers to suppress appetite, thereby reducing total caloric intake.
Pharmacokinetic Profile
Distribution & Half-Life: Thanks to its specialized fatty diacid moiety, Tirzep binds extensively to plasma albumin, resulting in an elimination half-life of approximately 5 days. This allows for a consistent, once-weekly injection cycle.
Metabolism: Metabolized safely via proteolytic cleavage of its peptide backbone, beta-oxidation of its fatty acid chain, and general amide hydrolysis.
Dosage & Administration
Route of Administration: Strictly via subcutaneous injection in the abdomen, thigh, or upper arm. Never inject intravenously or intramuscularly.
Titration Protocol: The recommended starting dosage is 2.5 mg injected subcutaneously once weekly.
Escalation Schedule: After exactly 4 weeks on the 2.5 mg induction phase, increase the dosage to 5 mg once weekly. If additional glycemic control or weight management is required, dosage can be scaled up in 2.5 mg increments after at least 4 weeks on the current dose, up to a maximum tier of 15 mg weekly.
Flexible Execution: Can be injected at any time of day, with or without meals. Rotate the injection site with every dose. If used alongside insulin, administer them as separate injections; never mix them in the same syringe.
Missed Dose Window: If a dose is missed, administer it as soon as possible within 4 days (96 hours). If more than 4 days have passed, skip the missed dose and resume on your regular weekly schedule day.
Clinical Considerations & Safety
Risk of Thyroid C-Cell Tumors (Boxed Warning): Tirzepatide is strictly contraindicated in patients with a personal or family history of Medullary Thyroid Carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
Pancreatitis Vigilance: Patients must be observed for persistent, severe abdominal pain radiating to the back. Discontinue immediately if pancreatitis is suspected.
Gastrointestinal Reactions: Nausea, diarrhea, decreased appetite, vomiting, constipation, dyspepsia, and abdominal pain are common. Starting at the 2.5 mg dose allows the gastrointestinal tract to acclimate, reducing the severity of these effects during treatment initiation.
Delayed Gastric Emptying (Oral Contraceptive Alert): Due to absorption delays caused by slower stomach emptying, patients using oral hormonal contraceptives should switch to a non-oral birth control method or add a secondary barrier method for 4 weeks after starting treatment and for 4 weeks following each subsequent dose escalation.
Storage, Packaging & Handling
Storage: Keep refrigerated at 2°C to 8°C. Protect from light. Do not freeze—if a pre-filled syringe has been frozen, it must be discarded.
Latex Caution: The needle cover of the pre-filled syringe contains dry natural rubber (a latex derivative), which may trigger allergic reactions in sensitive individuals.
Commercial Pack: Tirzep 2.5 mg is packaged as a precise 0.5 ml sterile solution inside a single-dose pre-filled syringe, complete with a first-aid bandage and an alcohol pad for immediate preparation.